Rosalind Advisors Inc. Sells 73,798 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Rosalind Advisors Inc. cut its holdings in COMPASS Pathways plc (NASDAQ:CMPS) by 9.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 707,625 shares of the company’s stock after selling 73,798 shares during the period. COMPASS Pathways comprises approximately 1.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 20th biggest holding. Rosalind Advisors Inc.’s holdings in COMPASS Pathways were worth $2,675,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Geode Capital Management LLC increased its position in shares of COMPASS Pathways by 160.3% during the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after purchasing an additional 25,970 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its position in COMPASS Pathways by 18.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company’s stock valued at $661,000 after buying an additional 26,787 shares during the period. Brown University increased its holdings in COMPASS Pathways by 194.6% during the fourth quarter. Brown University now owns 214,200 shares of the company’s stock worth $810,000 after buying an additional 141,500 shares during the last quarter. Conservest Capital Advisors Inc. raised its position in COMPASS Pathways by 28.9% in the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after acquiring an additional 3,000 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new position in COMPASS Pathways in the fourth quarter valued at about $41,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Friday, March 28th. Royal Bank of Canada restated an “outperform” rating and issued a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Canaccord Genuity Group dropped their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Stifel Nicolaus initiated coverage on COMPASS Pathways in a report on Thursday, February 27th. They issued a “buy” rating and a $11.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $20.20.

COMPASS Pathways Trading Up 1.6 %

NASDAQ:CMPS opened at $3.88 on Tuesday. COMPASS Pathways plc has a 1 year low of $2.49 and a 1 year high of $9.63. The stock’s fifty day moving average price is $3.34 and its two-hundred day moving average price is $4.16. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The company has a market cap of $359.57 million, a P/E ratio of -1.76 and a beta of 2.34.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, analysts expect that COMPASS Pathways plc will post -2.33 EPS for the current year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.